At least 2760 subjects have received IV levodopa, and reported outcomes include parkinsonian signs, sleep variables, hormone levels, hemodynamics, CSF amino acid composition, regional cerebral blood flow, cognition, perception and complex behavior.

2023年4月17日 · Levodopa is the precursor to dopamine. Most commonly, clinicians use levodopa as a dopamine replacement agent for the treatment of Parkinson disease. It is most effectively used to control bradykinetic symptoms apparent in Parkinson disease.

This “Cotzias regimen” , which is basically still used today, converted our dramatic short-lasting iv L-DOPA antiparkinson effect into a sustained dramatic improvement by oral L-DOPA. Nevertheless the road to this final victory in the L-DOPA drama, whose first act had started in 1961 in Vienna, with New York being the scene of its last act ...

L-多巴[2] （L -DOPA，levodopa）化学名 L-3,4-二羟苯丙氨酸，是 中枢神经系统 传导和调节剂，为 酪氨酸 经 酪氨酸羟化酶 的作用下羟化产生的氧化产物，具有 儿茶酚 羟基。 L -多巴可进一步生成另外一些有生物活性的物质，如： L -多巴在 酪氨酸酶 的作用下生成 多巴醌 继而自发转变为 黑色素，或在 芳香族氨基酸脱羧酶 的作用下生成 多巴胺，继而形成 去甲肾上腺素 与 肾上腺素 等。 ^ Howard ST, Hursthouse MB, Lehmann CW, Poyner EA. Experimental and theoretical …

At least 2760 subjects have received IV levodopa, and reported outcomes include parkinsonian signs, sleep variables, hormone levels, hemodynamics, CSF amino acid composition, regional cerebral blood flow, cognition, perception and complex behavior.

2023年8月1日 · IV delivery of lipid nanocarrier encapsulated L-DOPA resulted in slight improvement in 6-OHDA-induced parkinsonian disabilities similar to IV administered free L-DOPA, lasting for up to 24 h after NP encapsulation and 6 h for free L-DOPA.

In 1942, Holtz demonstrated that the administration of L-dopa in laboratory animals and humans results in excretion of dopamine in the urine. He noticed that in humans, 50 mg L-dopa intravenous (IV) caused tachycardia. Dopamine was isolated first …

2021年12月1日 · We found that high levels of serum E2 were associated with the upregulation of Syt IV and PRL in PRL-ir cells, while treatment with L-dopa decreased the size of prolactinomas and downregulated Syt IV but had no effect on PRL expression or serum concentrations.

1992年5月1日 · L-dopa (L-dihydroxyphenylalanine) remains the single most effective agent for the symptomatic treatment of Parkinson’s disease. With disease progression, however, 50% or more of this therapeutic success is contaminated by motor response fluctuations.

During IV infusions of L-dopa following oral administration of phenylalanine, a large neutral amino acid that shares a transport system into the brain with L-dopa, the duration of the motor response was markedly attenuated despite undiminished CSFv levels of L-dopa.